Vice President, Therapeutic Area Head – CardioMetabolism

Nod Thera is a clinical-stage biotechnology company pioneering a paradigm shift in the treatment of chronic inflammatory diseases. Our focus is on developing a new class of potent, highly selective, and brain-penetrant NLRP3 inflammasome inhibitors
. We have three therapeutic areas of focus- cardiometabolism, neuroinflammation, and peripheral inflammation. Of these, cardiometabolism is of highest priority as we advance rapidly through phase 2 into phase 3.

Unlike traditional approaches that block individual downstream cytokines, Nod Thera’s small molecules address the upstream catalyst of inflammation. With our lead candidate,
NT-0796
, we are uniquely positioned to address the "missing link" in cardiometabolic health: hypothalamic and systemic inflammation. Our recent data demonstrates that by resetting the body’s metabolic set-point and reducing markers like hsCRP, we can deliver cardiovascular risk reduction that rivals other mechanisms with the additional potential of metabolic benefits. To learn more about Nodthera see our website:

We are looking to hire a TA Head for Cardio Metabolism
, to join our team to drive our end-to-end clinical development strategy—from late-stage translation to registrational trials. This role will report directly to the CMO. In this role, S/he will be the clinical architect and strategic leader for our high profile clinical programs. S/he will join at a pivotal inflection point as we advance our RESOLVE program in cardiometabolism to phase 3.

• Clinical Strategy & Leadership: Refine and execute the global clinical development plan (CDP) for the Cardio Metabolic portfolio, ensuring alignment with Nod Thera’s mission to treat chronic inflammation at its source.
• Trial Oversight: Provide medical and strategic leadership for all clinical trials in cardiometabolism, ensuring high-quality data generation and clinical excellence.
• Trial Design Innovation: Working with our extensive set of experienced advisors you will spearhead innovative approaches in cardiometabolic clinical development in close partnership with regulatory and operational experts.
• Regulatory & Stakeholder Engagement: Act as the primary medical spokesperson for the TA with global regulatory agencies (FDA, EMA), the Board of Directors, and the investment community.
• Thought Leadership: Build and maintain deep relationships with Global Key Opinion Leaders (KOLs) in cardiology, endocrinology, and obesity. Present groundbreaking data at major medical congresses (ACC, AHA, ADA).
• Cross-Functional Collaboration: Partner with Research/Discovery to identify next-generation cardiometabolic targets and with Commercial/BD to shape the market-access strategy for a "best-in-class" oral inhibitor.

• MD or MD/PhD with board certification in Cardiology, Endocrinology, or a related field.
• Minimum of 8 years of drug development experience within biotech or pharmaceutical environments, with a proven track record of leading successful Phase 2/3 programs. Experience with cardiovascular outcome trials is essential.
• Expertise in Cardiometabolism: You must understand the evolving landscape of obesity, ASCVD risk reduction, and the role of inflammatory biomarkers (e.g., CRP, IL-1β, IL-6).
• Small Molecule & Immunology Fluency: Experience with immunology, and oral small-molecule development would be desirable.
• Strategic Agility: The ability to pivot between deep scientific "craftsmanship" and high-level corporate strategy.
• Communication: A "master of your craft" who can communicate complex science to diverse audiences—from academic experts to venture capital investors.

Qualified candidates should email resume / CV to